A collaboration between 34 researchers at 18 institutions has looked into the efficacy and safety of psilocybin in patients with major depressive disorder.
The psychedelic drug psilocybin, a naturally occurring compound found in some mushrooms, has been studied as a potential treatment for depression for years. But exactly how it works in the brain and how long beneficial results ...
Jul 5, 2021
0
814
Results from a Phase II clinical trial indicate that psilocybin, a hallucinogenic chemical found in certain mushrooms of the genus Psilocybe, may benefit individuals with cancer and major depression. Trial participants treated ...
Dec 18, 2023
0
249
In a small study of adults with major depression, Johns Hopkins Medicine researchers report that two doses of the psychedelic substance psilocybin, given with supportive psychotherapy, produced rapid and large reductions ...
Nov 4, 2020
4
739
Long-held beliefs can become entrenched over time, making them hard to change. But psychedelics might provide a way to alter them, a study suggests.
Jan 26, 2018
1
148
Following up on their landmark 2016 study, researchers at NYU Grossman School of Medicine found that a one-time, single-dose treatment of psilocybin, a compound found in psychedelic mushrooms, combined with psychotherapy ...
Jan 28, 2020
2
3469
Brain scans of people under the influence of the psilocybin, the active ingredient in magic mushrooms, have given scientists the most detailed picture to date of how psychedelic drugs work. The findings of two studies being ...
Jan 23, 2012
6
0
The latest study to examine how tiny amounts of psychedelics can impact mental health provides further evidence of the therapeutic potential of microdosing.
Jul 11, 2022
0
456
An international team of researchers has built a biophysically realistic whole-brain model to explain the impact of psilocybin on the brain. In their paper published in Proceedings of the National Academy of Sciences, the ...
A combined team of researchers from University Roma Tre and Nova Mentis Life Science Corp. has found that administering microdoses of psilocybin to rats with fragile X syndrome (FXS), an autism-like disease, improves some ...
